15.56
price down icon1.58%   -0.25
after-market Dopo l'orario di chiusura: 15.56
loading
Precedente Chiudi:
$15.81
Aprire:
$15.95
Volume 24 ore:
391.63K
Relative Volume:
0.37
Capitalizzazione di mercato:
$777.28M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-4.2168
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-1.46%
1M Prestazione:
+30.43%
6M Prestazione:
+77.83%
1 anno Prestazione:
+1.10%
Intervallo 1D:
Value
$15.53
$15.97
Intervallo di 1 settimana:
Value
$15.20
$16.23
Portata 52W:
Value
$7.30
$16.32

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Nome
Kalvista Pharmaceuticals Inc
Name
Telefono
(857) 999-0075
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
270
Name
Cinguettio
@kalvista
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
15.56 789.77M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato JMP Securities Mkt Outperform
2025-01-07 Iniziato TD Cowen Buy
2024-12-18 Iniziato BofA Securities Buy
2020-06-15 Iniziato H.C. Wainwright Buy
2019-07-29 Iniziato SVB Leerink Outperform
2019-03-20 Iniziato Needham Buy
2018-10-30 Iniziato Jefferies Buy
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2017-08-31 Iniziato BTIG Research Buy
Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
Jul 23, 2025

What analysts say about KalVista Pharmaceuticals Inc. stockRapidly growing investment returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jul 14, 2025
pulisher
Jul 13, 2025

Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 11, 2025

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $27 - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista price target raised to $27 from $19 at Citizens JMP - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Shares Fall After Fiscal 2025 Results - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener

Jul 10, 2025

Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):